{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:46:19Z","timestamp":1761237979450,"version":"3.40.4"},"reference-count":13,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":8377,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1990,4]]},"abstract":"<jats:p><jats:italic>The pharmacokinetics of phenylpropanolamine (PPA) were studied in five healthy male volunteers after single oral doses of 25, 50 and 100 mg of the drug as well as at steady state after seven, 4\u2010hourly doses of PPA. The peak serum concentrations and AUC<jats:sub>\u221e<\/jats:sub>values increased linearly with an increase in dose, whereas the time to reach peak serum concentrations did not vary significantly between doses. The half\u2010life remained relatively constant with an increase in dose (t<jats:sub>1\/2<\/jats:sub>= 3.8 to 4.3 hours), as did renal clearance (Cl<jats:sub>R<\/jats:sub>= 0.41 to 0.44 1\/kg\/h). The percentage of unchanged PPA excreted in the urine over a 14 hour period was 64%, 63% and 73% for the 25, 50 and 100 mg doses, respectively. The pharmacokinetics of PPA were found to be linear in the dosage range 25 to 100 mg. Steady state serum concentrations were significantly higher than single dose concentrations, with the mean peak serum concentration increasing from 113 ng\/ml after a single dose to 183 ng\/ml at steady state. The time at which these were attained decreased from 1.47 hours after a single dose to 0.73 hours at steady state. Both clearance and volume of distribution were significantly different after a single dose compared to steady state (<\/jats:italic>P<jats:italic>&lt;0.05), whereas no significant differences were found between the other parameters<\/jats:italic>.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1990.tb03608.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T21:34:22Z","timestamp":1362778462000},"page":"372-377","source":"Crossref","is-referenced-by-count":16,"title":["Steady State Pharmacokinetics and Dose\u2010Proportionality of Phenylpropanolamine in Healthy Subjects"],"prefix":"10.1002","volume":"30","author":[{"given":"S. S.","family":"Scherzinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dowse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Kanfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"volume-title":"Phenylpropanolamine\u2014A Review","year":"1988","author":"Lasagna L","key":"e_1_2_1_2_2"},{"volume-title":"Phenylpropanolamine. Risks, Benefits and Controversies","year":"1985","author":"Morgan JP","key":"e_1_2_1_3_2"},{"key":"e_1_2_1_4_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(25)28008-9","article-title":"Absorption, metabolism and excretion of the ephedrines in man I. The influence of urinary pH and urine volume output","volume":"162","author":"Wilkinson GR","year":"1968","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600571122"},{"key":"e_1_2_1_6_2","first-page":"39","article-title":"Steady\u2010state kinetics of sustained\u2010release phenylpropanolamine","volume":"22","author":"Lonnerholm G","year":"1984","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(87)90209-2"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015948403476"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600500313"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600720912"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00606417"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600520629"},{"key":"e_1_2_1_13_2","unstructured":"DowseR:Biopharmaceutics of Phenylpropanolamine.Ph.D Thesis Rhodes University Grahamstown South Africa 1984."},{"volume-title":"Pharmacokinetics","year":"1984","author":"Gibaldi M","key":"e_1_2_1_14_2"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1990.tb03608.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1990.tb03608.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T23:39:48Z","timestamp":1745969988000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1990.tb03608.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,4]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1990,4]]}},"alternative-id":["10.1002\/j.1552-4604.1990.tb03608.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1990.tb03608.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"type":"print","value":"0091-2700"},{"type":"electronic","value":"1552-4604"}],"subject":[],"published":{"date-parts":[[1990,4]]}}}